Emily Chou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emily Chou has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ann Ly
Department of Urology, University of California, Los Angeles, California. 1
64 shared publications - Arnold I. Chin
University of California, Los Angeles 4 Los Angeles, CA
64 shared publications - Hanwei Zhang
Department of Urology, University of California, Los Angeles, California. 1
64 shared publications - Kris Prado
Department of Urology, Stanford University, Stanford, USA
64 shared publications - Liang Wang
Department of Pharmacology and Toxicology, Department of Urology, Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, USA
64 shared publications - Matteo Pellegrini
Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, USA
64 shared publications
Latest Publications
- Open Access
- 22 October 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (11) , 102259
Statin Use in Patients With Cancer
- 22 October 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (11) , 102259
Open AccessStatin Use in Patients With Cancer
- Open Access
- 22 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2667
RELT Is Upregulated in Breast Cancer and Induces Death in Breast Cancer Cells
Background: Receptor Expressed in Lymphoid Tissues (RELT) is a TNFRSF member that has two paralogs, RELL1 and RELL2; the three proteins are collectively referred to as RELT family members (RELTfms). Methods: We sought to evaluate RELT expression in cancerous cells by using real-time PCR, western blotting, flow cytometry, and immunohistochemistry (IHC). The mechanism of RELT-induced cell death was assessed by western blotting, flow cytometry, luciferase assays, and morphology staining. RELT localization was detected through immunofluorescence and western blotting, and co-immunoprecipitation was used to test whether a mutated RELT interacts with the OXSR1 kinase. Results: RELT and RELL1 protein expression was significantly elevated in cell lines representing breast and lung cancer, whereas RELL2 protein expression was relatively consistent across different cell lines. The surface expression of RELT was highest in monocytes. IHC staining revealed increased RELT expression in malignant breast cancer biopsies compared to patient-matched benign tissue. RELTfm overexpression induced death in MDA-MB-231 (231) breast cancer cells, accompanied by increased phosphatidylserine externalization and Caspase-3/7 activation. The co-transfection of plasmids predicted to block the phosphorylation of RELT by the OXSR1 kinase did not abrogate RELT-induced apoptosis, indicating that the activation of p38 by RELT through the OXSR1 kinase is not required for RELT-induced cell death. Interestingly, nuclear localization of RELT was detected in 231 and HEK-293 cells. Conclusions: These results demonstrate that RELT induces death in breast cancer cells through an apoptotic pathway that does not require OXSR1 phosphorylation and that RELT possesses the ability to translocate to the nucleus, a novel finding that warrants further investigation.
- 22 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2667
Open AccessRELT Is Upregulated in Breast Cancer and Induces Death in Breast Cancer Cells
Background: Receptor Expressed in Lymphoid Tissues (RELT) is a TNFRSF member that has two paralogs, RELL1 and RELL2; the three proteins are collectively referred to as RELT family members (RELTfms). Methods: We sought to evaluate RELT expression in cancerous cells by using real-time PCR, western blotting, flow cytometry, and immunohistochemistry (IHC). The mechanism of RELT-induced cell death was assessed by western blotting, flow cytometry, luciferase assays, and morphology staining. RELT localization was detected through immunofluorescence and western blotting, and co-immunoprecipitation was used to test whether a mutated RELT interacts with the OXSR1 kinase. Results: RELT and RELL1 protein expression was significantly elevated in cell lines representing breast and lung cancer, whereas RELL2 protein expression was relatively consistent across different cell lines. The surface expression of RELT was highest in monocytes. IHC staining revealed increased RELT expression in malignant breast cancer biopsies compared to patient-matched benign tissue. RELTfm overexpression induced death in MDA-MB-231 (231) breast cancer cells, accompanied by increased phosphatidylserine externalization and Caspase-3/7 activation. The co-transfection of plasmids predicted to block the phosphorylation of RELT by the OXSR1 kinase did not abrogate RELT-induced apoptosis, indicating that the activation of p38 by RELT through the OXSR1 kinase is not required for RELT-induced cell death. Interestingly, nuclear localization of RELT was detected in 231 and HEK-293 cells. Conclusions: These results demonstrate that RELT induces death in breast cancer cells through an apoptotic pathway that does not require OXSR1 phosphorylation and that RELT possesses the ability to translocate to the nucleus, a novel finding that warrants further investigation.
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FDRs and p-values of IFNgamma induced genes
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FDRs and p-values of IFNgamma induced genes
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Normalized gene expression of RNA sequencing
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Normalized gene expression of RNA sequencing
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FOXP3 antibodies not sufficient for ChIP Sequencing
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FOXP3 antibodies not sufficient for ChIP Sequencing
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Minimal activation of PD-L1 by IL-4 and IL-10 compared to IFNgamma in HT1376 cells
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Minimal activation of PD-L1 by IL-4 and IL-10 compared to IFNgamma in HT1376 cells
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Generation of MB49 FOXP3 knockout cells by flow cytometry and Western blot. Immunofluorescence of chromogranin A and NSE.
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Generation of MB49 FOXP3 knockout cells by flow cytometry and Western blot. Immunofluorescence of chromogranin A and NSE.